Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 5,569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Neuropathy in ATTRv

NCT05311488
View directory record Official record
Conditions
Hereditary Amyloidosis, Transthyretin-Related
Interventions
neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis

NCT05979688
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Myasthenia Gravis
Interventions
yogic breathing exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 30, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

NCT07748403
View directory record Official record
Conditions
Wilson Disease, Wilson's Disease, Wilsons Disease
Interventions
PM577a
Drug
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 9:03 PM EDT
Withdrawn No phase listed Observational

A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

NCT07075627
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC ), Lambert Eaton Myasthenic Syndrome (LEMS)
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 9:03 PM EDT
Completed No phase listed Observational

Natural History Study of CEP290-Related Retinal Degeneration

NCT03396042
View directory record Official record
Conditions
Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration
Interventions
Not listed
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00125203
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Sialorrhea
Interventions
Botulinum toxin type B (Myobloc), Injection of salivary glands
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Kansas City, Kansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

NCT03115827
View directory record Official record
Conditions
Parkinson Disease
Interventions
Droxidopa, Carbidopa
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 30, 2026, 9:03 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis

NCT01508962
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2037
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

NCT00920946
View directory record Official record
Conditions
Huntington Disease
Interventions
Dimebon, Placebo
Drug · Other
Lead sponsor
Medivation, Inc.
Industry
Eligibility
30 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
24
States / cities
Scottsdale, Arizona • Davis, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 30, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

NCT03919162
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 30, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

NCT00299988
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Intravenous Immunoglobulin, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Agitation in Alzheimer's Disease

NCT00000179
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Trazodone, Haloperidol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 9:03 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

NCT04726527
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease, Dementia
Interventions
Florbetapir F 18, Positron Emission Tomography
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia

NCT02415127
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Interferon γ-1b, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Methylphenidate and Parkinson's Disease

NCT00359723
View directory record Official record
Conditions
Parkinson's Disease
Interventions
methylphenidate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease

NCT02725580
View directory record Official record
Conditions
Variant Late-Infantile Neuronal Ceroid Lipofuscinosis
Interventions
AT-GTX-501
Genetic
Lead sponsor
Emily de los Reyes
Other
Eligibility
1 Year and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Coadministration of Begacestat And Donepezil

NCT00959881
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil plus placebo, Donepezil, Begacestat
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Oct 30, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial on Agitation in Alzheimer's Dementia

NCT05543681
View directory record Official record
Conditions
Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions
IGC-AD1-Active, IGC-AD1-Placebo
Drug
Lead sponsor
IGC Pharma, LLC
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Light Therapy Intervention in Individuals With Parkinson's Disease

NCT06916260
View directory record Official record
Conditions
Parkinson Disease
Interventions
Red Light (PDT), Placebo
Device
Lead sponsor
University of Delaware
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CODY (Co-design for You): An Immersive Technology Tool for Experiencing and Assessing Home Alterations

NCT03961282
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Doorway Width Test, Door Frame Color Test
Other
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 92 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 30, 2026, 9:03 PM EDT
Completed No phase listed Observational

Objective, Passive Assessment of LRRK2 Carriers

NCT05287620
View directory record Official record
Conditions
Parkinson Disease
Interventions
Emerald device
Device
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

NCT00880620
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD, IPX066 245 mg LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Garden Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 30, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

NCT03462680
View directory record Official record
Conditions
Parkinson's Disease
Interventions
niacin, placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 30, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3954068, Placebo, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 9:03 PM EDT